212,209 Shares in Evolus, Inc. (NASDAQ:EOLS) Acquired by Walleye Capital LLC

Walleye Capital LLC acquired a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 212,209 shares of the company's stock, valued at approximately $3,438,000. Walleye Capital LLC owned approximately 0.34% of Evolus at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Assenagon Asset Management S.A. lifted its holdings in shares of Evolus by 5,627.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company's stock worth $10,276,000 after acquiring an additional 930,566 shares during the last quarter. Armistice Capital LLC bought a new stake in shares of Evolus in the 2nd quarter worth approximately $3,906,000. Charles Schwab Investment Management Inc. raised its holdings in Evolus by 173.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company's stock valued at $6,781,000 after buying an additional 265,635 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Evolus during the 2nd quarter valued at $1,326,000. Finally, GSA Capital Partners LLP raised its holdings in Evolus by 335.3% during the 3rd quarter. GSA Capital Partners LLP now owns 120,964 shares of the company's stock valued at $1,960,000 after buying an additional 93,176 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.

Insider Buying and Selling

In related news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company's stock, valued at approximately $2,224,559.96. This represents a 2.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on EOLS. Barclays upped their price target on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, September 13th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Evolus in a report on Friday, September 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a report on Monday, September 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, November 7th.

Evolus Trading Down 3.0 %

Shares of EOLS stock traded down $0.41 during mid-day trading on Tuesday, reaching $13.10. 440,189 shares of the company's stock traded hands, compared to its average volume of 593,893. The company's 50-day moving average price is $15.22 and its 200-day moving average price is $13.88. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a 12 month low of $9.38 and a 12 month high of $17.82.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.